<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83241060-3BAD-499D-BA72-380013794CC6"><gtr:id>83241060-3BAD-499D-BA72-380013794CC6</gtr:id><gtr:name>Abbott</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCC1D331-F7AC-45F0-BB6E-781675305ED5"><gtr:id>FCC1D331-F7AC-45F0-BB6E-781675305ED5</gtr:id><gtr:name>Gemin X Pharmaceuticals</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83241060-3BAD-499D-BA72-380013794CC6"><gtr:id>83241060-3BAD-499D-BA72-380013794CC6</gtr:id><gtr:name>Abbott</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCC1D331-F7AC-45F0-BB6E-781675305ED5"><gtr:id>FCC1D331-F7AC-45F0-BB6E-781675305ED5</gtr:id><gtr:name>Gemin X Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1797F7DA-C4D3-4BB2-8124-06CDBCB68A13"><gtr:id>1797F7DA-C4D3-4BB2-8124-06CDBCB68A13</gtr:id><gtr:firstName>Gerald Michael</gtr:firstName><gtr:surname>Cohen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U132615750"><gtr:id>0839D990-B638-4E71-BD15-EFC8B0B5252B</gtr:id><gtr:title>Molecular determinants of apoptosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U132615750</gtr:grantReference><gtr:abstractText>Neuro-degenerative diseases, such as Alzheimers and Parkinsons disease, as well as ischaemic injury caused by myocardial infarction and stroke, are characterised by excessive cell death. Conversely other diseases, such as cancer, are characterised by an accumulation of cells. The accumulation of cells in cancer is caused both by an increase in cell division and/or a failure of cells to die. One of the major ways that cells die is by a controlled programme referred to as apoptosis. Many chemicals, drugs and environmental agents also cause cells to die by apoptosis.||We have been studying the fundamental mechanisms of apoptosis. This knowledge can then be applied to help us treat certain diseases, such as chronic lymphocytic leukaemia (CLL), the major form of leukaemia in the UK. Based on our current studies, it is hoped to commence a clinical trial in Leicester.||By understanding how cells die can also help us prevent the unwanted side effects of some commonly used drugs.</gtr:abstractText><gtr:technicalSummary>Toxic agents including chemical and natural toxins can either kill cells or interfere with their death programmes. Drugs that trigger cell death to eliminate unwanted cells (i.e., cancer cells) or that prevent cell death in toxic and disease states have been and are currently being developed. Understanding cell death mechanisms is therefore central both in Toxicology and also at the early stages of drug design. Apoptosis is a physiological form of cell death, of considerable importance in developmental biology and tissue homeostasis. Inappropriate apoptosis is of importance in many common chronic diseases such as cancer, cardiovascular disease, autoimmune disease and neurodegenerative disease and may be triggered by environmental contaminants and toxins.||Research in our group has concentrated on understanding fundamental mechanisms of apoptosis. Our initial work was related to the mechanisms of DNA fragmentation and the involvement of caspases in apoptosis. More recently our work has concentrated on mechanisms of death receptor-induced apoptosis and chemical- or stress-induced apoptosis and has established that distinct caspase cascades are initiated in these processes. Our current emphasis has been on studying the mechanism of induction of apoptosis of potential chemotherapeutic agents in primary malignant B-cells from patients. This has highlighted important differences in the responses of primary cells compared to cell lines. This work has important translational implications and is being used to inform clinical trials, which it is hoped will commence in Leicester in the next year.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1992-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>7121435</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Abbott</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Action of ABT-737 on primary CLL cells in collaboration with Abbott.</gtr:description><gtr:id>86DAD4C3-1629-48EE-B97F-92523E990AD5</gtr:id><gtr:impact>This has resulted in a number of publications. A clinical trial of ABT-263in chronic lymphocytic leukaemia has now started in Leicester.</gtr:impact><gtr:outcomeId>122C9AE7A59-1</gtr:outcomeId><gtr:partnerContribution>They have provided materials as well as scientific data.They have provided materials as well as some scientific data.</gtr:partnerContribution><gtr:piContribution>We have continued studying the mechanism of apoptosis induction by ABT-737. This work has now been extended to the related analogue ABT-263, which is orally active and is being used in the clinical trials.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemin X Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Action of Obatoclax.</gtr:description><gtr:id>F645AD17-A95C-40A8-AB8D-74A541D00831</gtr:id><gtr:impact>Material supplied to investigate mechanism of action in CLL. This work has resulted in a publication in Cell Death and Differentiation.</gtr:impact><gtr:outcomeId>645B81B9E4B-1</gtr:outcomeId><gtr:partnerContribution>Material supplied to investigate mechanism of action in CLL</gtr:partnerContribution><gtr:piContribution>We have studied the mechanis of induction of cell death by Obatoclax using both standard biochemical and flow cytometric assays as well as an investigation of ultrastrutural changes.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Abbott</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Action of ABT-737 on primary CLL cells in collaboration with Abbott.</gtr:description><gtr:id>C35A9FCF-8CAB-4FCA-8BBD-FEDA86689C10</gtr:id><gtr:impact>This has resulted in a number of publications. A clinical trial of ABT-263in chronic lymphocytic leukaemia has now started in Leicester.</gtr:impact><gtr:outcomeId>122C9AE7A59-2</gtr:outcomeId><gtr:partnerContribution>They have provided materials as well as scientific data.They have provided materials as well as some scientific data.</gtr:partnerContribution><gtr:piContribution>We have continued studying the mechanism of apoptosis induction by ABT-737. This work has now been extended to the related analogue ABT-263, which is orally active and is being used in the clinical trials.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>141845</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Project Grant</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>0EE5940C-F545-4B07-B4F2-FC2A681B9D28</gtr:id><gtr:outcomeId>404D888E2200</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Servier</gtr:description><gtr:fundingOrg>Servier Laboratories</gtr:fundingOrg><gtr:id>F779A757-0736-43AE-813E-D36975846C66</gtr:id><gtr:outcomeId>AcrABowZQrU</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120684</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NWCR project grants</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:fundingRef>JXR11556</gtr:fundingRef><gtr:id>DF4C49FF-770E-4CE2-A9BE-62FD64F6A045</gtr:id><gtr:outcomeId>58c802846e91d9.57577909</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>558925</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N00941X/1</gtr:fundingRef><gtr:id>1D3FF171-5B8E-4DC7-B027-44EB9BE449F6</gtr:id><gtr:outcomeId>58c80c9d480852.07944871</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>134689</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant NWCR</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:fundingRef>CR 1040</gtr:fundingRef><gtr:id>295289FE-5832-41A1-B781-C3D054C8460C</gtr:id><gtr:outcomeId>58c810273abef7.08282244</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192243</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant NWCR</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:fundingRef>CR1127</gtr:fundingRef><gtr:id>C38D3924-4E03-4832-8F6B-4E0705FEAD81</gtr:id><gtr:outcomeId>58c80ea56ca491.19490820</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Together with my colleague Dr Marion MacFarlane we have shown the importance of using TRAIL-R1 in order to induce apoptosis in primary tumour cellsl from patients with CLL.</gtr:description><gtr:grantRef>MC_U132615750</gtr:grantRef><gtr:id>0C2CDA9D-5ECE-4C26-A909-A603E3DDC332</gtr:id><gtr:impact>This patent identifies mutants of the TNF-related Apoptosis inducing Ligand (TRAIL) with specificity for Death Receptor 4 over Death Receptor 5. These have application in the treatment of cancer, particularly B cell malignancies, and with a lower liver toxicity than normal TRAIL National phase</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>FB002BEA015</gtr:outcomeId><gtr:patentId>US2009325867</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>TRAIL mutants</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Blood</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>02D53E9D-3510-4027-ACA2-7C8C11D6626B</gtr:id><gtr:impact>This work should help in treatment of chronic lymphocytic leukaemia.</gtr:impact><gtr:outcomeId>509E6064494</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>06FD12D1-E627-4BA7-9AE4-7CEE4CCD9A10</gtr:id><gtr:title>Caspase-9 cleavage, do you need it?</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43e947dc2345d09f34cab9fb38c41c6a"><gtr:id>43e947dc2345d09f34cab9fb38c41c6a</gtr:id><gtr:otherNames>Twiddy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>99CDCE97E14</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37E67AD9-9188-496C-A71E-250FF15E5317</gtr:id><gtr:title>The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>pm_13726_26_21514278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D163C08F-8DBC-4DA4-8E94-2373CFD01018</gtr:id><gtr:title>A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>C4ECA4ED738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>838974DA-0C24-47A0-87C1-DD8FDFD6B64A</gtr:id><gtr:title>Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>0EA0AF7857C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C51B9687-A9C4-4991-955D-CD03488BC0BD</gtr:id><gtr:title>The in vitro cleavage of the hAtg proteins by cell death proteases.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86c2a2bd8e4e27cfb09b78da53de3d33"><gtr:id>86c2a2bd8e4e27cfb09b78da53de3d33</gtr:id><gtr:otherNames>Norman JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>MkxoKSQPp6F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F322198C-3AC1-43E0-B5A1-A0CE9F70C7E3</gtr:id><gtr:title>The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a51ccb85828111a809a9225c3c8d02ba"><gtr:id>a51ccb85828111a809a9225c3c8d02ba</gtr:id><gtr:otherNames>Choi YE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CEB216FB1CD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48C46B6F-56D9-4EB5-8CC5-610943F21390</gtr:id><gtr:title>TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3f2b00254fefc176c70ca61cec715ed"><gtr:id>c3f2b00254fefc176c70ca61cec715ed</gtr:id><gtr:otherNames>Stadel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>rBdh5ayeX9U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18304687-B97C-4210-9DE0-8B2CA1993C67</gtr:id><gtr:title>Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9d7587f4ad96c426ef860b78d68e47b"><gtr:id>b9d7587f4ad96c426ef860b78d68e47b</gtr:id><gtr:otherNames>Mercer AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>801A9D64F38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97612BE0-C0BA-4AB5-B6A2-F1EF8221CBD2</gtr:id><gtr:title>Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>3DCC4176979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4E3E6FF-F3A5-49F9-954D-11ADDDA2D5C6</gtr:id><gtr:title>BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfd90a9b2d277dad4be92bfa2e99f933"><gtr:id>bfd90a9b2d277dad4be92bfa2e99f933</gtr:id><gtr:otherNames>Butterworth M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56e05994eda963.13394963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98296C09-05C8-4E33-9575-C65755659482</gtr:id><gtr:title>Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09b1298cf346413816e3a24b41021b8c"><gtr:id>09b1298cf346413816e3a24b41021b8c</gtr:id><gtr:otherNames>Baou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>fhPuLJ2taPL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0F2B7AD-297D-418D-8F59-98A909D520B3</gtr:id><gtr:title>BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>RsM3ftzFWcv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AD7F1BE-513E-475A-B307-4677A396D117</gtr:id><gtr:title>DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4611475df200eb5d57ddc81bbaf545a8"><gtr:id>4611475df200eb5d57ddc81bbaf545a8</gtr:id><gtr:otherNames>Milani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58987a12615550.34243755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9DC9CDA-3BBF-4972-B847-4D3439524240</gtr:id><gtr:title>p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/247414815407f8c50511cf613d791a43"><gtr:id>247414815407f8c50511cf613d791a43</gtr:id><gtr:otherNames>Rivetti di Val Cervo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>F5D2899219B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>560864B6-D529-4CAA-BBA6-22AB0F87CB3C</gtr:id><gtr:title>BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a105e2087643e57906cb9fca738accbc"><gtr:id>a105e2087643e57906cb9fca738accbc</gtr:id><gtr:otherNames>Weber K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56e05994b06604.51266247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C53A1D2-8835-4CEE-80C4-83BE552B06F5</gtr:id><gtr:title>Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfd90a9b2d277dad4be92bfa2e99f933"><gtr:id>bfd90a9b2d277dad4be92bfa2e99f933</gtr:id><gtr:otherNames>Butterworth M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>947571BF7D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>686BAFDD-E30C-4A27-B805-4227F7084647</gtr:id><gtr:title>Different forms of cell death induced by putative BCL2 inhibitors.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>5F725EF554F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4267C2DB-A1DA-487E-97B4-BD95AF4D3202</gtr:id><gtr:title>Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>C4746CA3115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56EEBA4C-F759-4D5F-BEFA-6B1426F2B361</gtr:id><gtr:title>Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/965d8feba4031afcf8a01b411c83a7a0"><gtr:id>965d8feba4031afcf8a01b411c83a7a0</gtr:id><gtr:otherNames>Sayan BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>382642E49D7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0109783-E69F-4728-8ADD-0F384C7EAD8E</gtr:id><gtr:title>Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>ED179FC50F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21BE1620-E606-420E-8541-16DF4E784FC8</gtr:id><gtr:title>High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/726ca869ae597731dd3f2a4fb0265089"><gtr:id>726ca869ae597731dd3f2a4fb0265089</gtr:id><gtr:otherNames>Lucas CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>56e059951c5a81.32999532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF80AEFF-BB37-4C57-ADF7-C00826ADA248</gtr:id><gtr:title>Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis</gtr:title><gtr:parentPublicationTitle>Neoplasia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fdf26bbdbea99a0ce0f88b637b8fcf4"><gtr:id>6fdf26bbdbea99a0ce0f88b637b8fcf4</gtr:id><gtr:otherNames>Varadarajan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56e059945258a0.34509577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5FD6CA4-FF82-46A7-BD0D-A315BC418F8A</gtr:id><gtr:title>Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/531f31c3acea31db910212a6fc05967e"><gtr:id>531f31c3acea31db910212a6fc05967e</gtr:id><gtr:otherNames>Kohlhaas SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>34A6337A579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59B834A6-1258-4477-8C5C-0DA63B970423</gtr:id><gtr:title>Barriers to effective TRAIL-targeted therapy of malignancy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>293EC222565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5234CB57-77E0-47E1-AEAA-8EBAAFF6DB5C</gtr:id><gtr:title>Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>8F965E86A3A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>242B13B5-808B-4FF2-8339-F1F41BE2D73B</gtr:id><gtr:title>Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8586545a7debb2a2b47fa2bfe7a5b80b"><gtr:id>8586545a7debb2a2b47fa2bfe7a5b80b</gtr:id><gtr:otherNames>Hughes MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>4F36A372BB5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F575830E-D9CB-4050-82D9-EEA5D81FEEA4</gtr:id><gtr:title>A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fdf26bbdbea99a0ce0f88b637b8fcf4"><gtr:id>6fdf26bbdbea99a0ce0f88b637b8fcf4</gtr:id><gtr:otherNames>Varadarajan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_13726_26_22955944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F619EEA5-8A12-4E5A-B095-80449805768A</gtr:id><gtr:title>Death receptor-induced apoptosis reveals a novel interplay between the chromosomal passenger complex and CENP-C during interphase.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10a9e20ab8ad5f1f3f6835d9b7901582"><gtr:id>10a9e20ab8ad5f1f3f6835d9b7901582</gtr:id><gtr:otherNames>Faragher AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>BAA7F5CDA2A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA27577E-2B40-482F-B63D-9D858EDC578F</gtr:id><gtr:title>TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7646eb6d6d6dc2890439db5ed02c07"><gtr:id>4a7646eb6d6d6dc2890439db5ed02c07</gtr:id><gtr:otherNames>Natoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>6373EA2CAE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61B6745D-4CAB-420E-84B4-7F383059A396</gtr:id><gtr:title>ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56e05994739166.67517038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAB6BC1B-9C34-4C84-BB9F-5DA9F69A02CB</gtr:id><gtr:title>Evaluation and critical assessment of putative MCL-1 inhibitors.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fdf26bbdbea99a0ce0f88b637b8fcf4"><gtr:id>6fdf26bbdbea99a0ce0f88b637b8fcf4</gtr:id><gtr:otherNames>Varadarajan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>56e05994919ff4.47190703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24EB7C29-7DBA-448E-9DA0-5F2D9D6E24D7</gtr:id><gtr:title>Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>rdDsK1kWnRt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F5E7EDC-1BA3-4CAE-A24D-25068C526C1B</gtr:id><gtr:title>NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67f1b69c978cedf569c15eb799a7c4df"><gtr:id>67f1b69c978cedf569c15eb799a7c4df</gtr:id><gtr:otherNames>Craxton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_13726_26_22361683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DEB6064-00F4-4BE9-9A75-5756121487B7</gtr:id><gtr:title>Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>V2sitmDv6gJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3738E36C-F04F-4D6E-AFF5-A8CCE0A53C05</gtr:id><gtr:title>Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cf3c7f03f6271218f79ff9e67caedeb"><gtr:id>5cf3c7f03f6271218f79ff9e67caedeb</gtr:id><gtr:otherNames>Volkmann X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>6E81D85B0DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D95FB9A-8BBB-4CD1-8817-5ABFDCDCF438</gtr:id><gtr:title>Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fdf26bbdbea99a0ce0f88b637b8fcf4"><gtr:id>6fdf26bbdbea99a0ce0f88b637b8fcf4</gtr:id><gtr:otherNames>Varadarajan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58987ac73b6cb8.68573154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2783A06-0A2D-4BB0-9B05-22C744976B9E</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f446e86d6836d8e6a5da49dfe563b87"><gtr:id>8f446e86d6836d8e6a5da49dfe563b87</gtr:id><gtr:otherNames>Galluzzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>fgZ6Xzyudpz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8374031F-FA97-42E2-B962-A0C030CF7FF4</gtr:id><gtr:title>Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>F99AECFA660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB41D848-24A0-4380-A294-692907CA6BF1</gtr:id><gtr:title>The transrepression arm of glucocorticoid receptor signaling is protective in mutant huntingtin-mediated neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fdf26bbdbea99a0ce0f88b637b8fcf4"><gtr:id>6fdf26bbdbea99a0ce0f88b637b8fcf4</gtr:id><gtr:otherNames>Varadarajan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>56e05994cdc690.71796410</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U132615750</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>